ETFs positioned on AstraZeneca PLC

Name YTD change Weight AuM
+13.79%-.--% 27,154 M€
+11.27%-.--% 2,627 M€
-.--%-.--% 22 M€
+1.65%-.--% 51 M€
+12.11%-.--% 122 M€
+3.47%-.--% 293 M€
+12.82%-.--% 3,469 M€
+11.68%-.--% 6,576 M€
+1.29%17.21% 391 M€
+1.32%15.79% 1,024 M€
-0.42%15.25% 820 M€
+2.25%13.81% 667 M€
+8.38%9.6% 106 M€
+8.21%9.6% 147 M€
+6.70%9.6% 19 M€
+11.52%9.6% 1,166 M€
+11.30%9.5% 2,462 M€
+7.94%9.5% 428 M€
+11.63%9.32% 158 M€
+11.14%9.22% 265 M€
+10.80%9.07% 935 M€
-.--%8.9% 1,190 M€
+8.20%8.9% 1,190 M€
+12.35%8.88% 38 M€
+9.67%8.88% 90 M€
+10.05%8.7% 679 M€
+11.87%8.68% 1,211 M€
+8.58%8.64% 44 M€
+10.39%8.6% 3,929 M€
+9.17%8.58% 6,358 M€
-.--%8.57% 122 M€
+11.72%8.57% 122 M€
+11.62%8.56% 4,353 M€
+11.64%8.56% 225 M€
+10.76%8.53% 54 M€
+7.76%8.39% 56 M€
+11.34%8.3% 19 M€
-.--%8.11% 114 M€
+10.43%8.11% 114 M€
+9.67%7.88% 158 M€
+11.04%7.83% 97 M€
+11.93%7.57% 22,220 M€
+11.75%7.55% 544 M€
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100
  1. Stock Market
  2. Stocks
  3. AZN Stock
  4. ETFs AstraZeneca PLC